Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
23847studies shown
Showing 8,521-8,532 of 23,847
Drug study icon
CompletedNCT02713282

Transition to the Paliperidone Palmitate 3-Month Formulation for schizophrenia

This study is completed in France, in the United Kingdom, in Croatia, .... It is testing Transition to the Paliperidone Palmitate 3-Month Formulation for schizophrenia.

Multiple locations, including Rijeka
SchizophreniaDrugA study involving a medication or substance.From 18 Years to 50 Years
Countries
France, United Kingdom, Croatia, ...
Sponsor
Janssen-Cilag Ltd.
Condition
Schizophrenia
Drug study icon
CompletedNCT00216632

Treatment Success for Schizophrenia

This study is completed. It is testing treatment Success for Schizophrenia.

Location not clearly listed
SchizophreniaDrugOver 18 Years
Countries
Sponsor
Janssen Pharmaceutica N.V., Belgium
Condition
Schizophrenia
Drug study icon
CompletedNCT00645320

Ziprasidone for Schizophrenia

This study is completed in Brazil. It is testing ziprasidone for Schizophrenia.

Multiple locations, including RIO de Janeiro RJ
SchizophreniaDrugFrom 18 Years to 55 Years
Countries
Brazil
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT04132557

A Study on Suicide prevention, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

This study exists to learn from real-world information that can show how a therapy or guided support program fits into care. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

In Titusville
Suicidality, SchizophreniaDrug
Countries
United States
Sponsor
Janssen Research & Development, LLC
Condition
Suicidality, Schizophrenia
Other study type icon
CompletedNCT01932398

A Study on the Inter-Hemispheric Alpha Ratio in Kids With ADHD (SHARK)

This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.

In Nijmegen
ADHDOtherFrom 84 Months to 95 Months
Countries
Netherlands
Sponsor
Radboud University Medical Center
Condition
ADHD
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.